Loading...
•
Dec 31, 2023
Maravai Q4 2023 Earnings Report
Reported financial results showing a decrease in revenue compared to the same period in the previous year, influenced by reduced COVID-19 related revenue and challenging industry conditions.
Key Takeaways
Maravai LifeSciences reported a Q4 2023 revenue of $74.1 million, a net loss of $(110.0) million, and an adjusted EBITDA margin of 28%. The revenue decrease was primarily driven by a significant decline in Nucleic Acid Production revenue, including COVID-19 related CleanCap revenue. The company is focusing on expanding its product portfolio and market leadership.
Q4 revenue was $74.1 million, a 64% decrease year-over-year.
Net loss for Q4 was $(110.0) million, compared to net income of $87.4 million in the same period last year.
Adjusted EBITDA margin for Q4 was 28%.
Full year 2024 revenue guidance is projected to be in the range of $265.0 million to $285.0 million.
Revenue by Segment
Forward Guidance
Maravai projects revenue for 2024 to be in the range of $265.0 million to $285.0 million, with adjusted EBITDA margins expected to be in the range of 23% to 25%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...